patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_884968 | REC_0002701 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 16.3 | 61 | female | 1 | 14 | 5.2 | 2 | osimertinib 80 mg daily | 23.6 | true | MSI-H | 2026-03-15T05:35:57.510717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525666 | REC_0002702 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.1 | 46 | male | 0 | 49 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:57.510949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398052 | REC_0002703 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.7 | 61 | female | 1 | 15 | 7.3 | 7 | entrectinib 600 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:35:57.511187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644237 | REC_0002704 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 9 | 62 | male | 1 | 12 | 3.6 | 8 | pembrolizumab 200 mg q3w | 16.3 | true | MSS | 2026-03-15T05:35:57.511418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701252 | REC_0002705 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.5 | 57 | female | 1 | 14 | 5.3 | 5 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:57.511700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931779 | REC_0002706 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.3 | 46 | male | 0 | 13 | 5.5 | 2 | pembrolizumab 200 mg q3w | 18.9 | false | MSS | 2026-03-15T05:35:57.511934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246452 | REC_0002707 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 18.1 | 60 | female | 0 | 13 | 6 | 5 | alectinib 600 mg BID | 9.9 | false | MSI-H | 2026-03-15T05:35:57.512218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800830 | REC_0002708 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10 | 65 | female | 1 | 24 | 5.5 | 5 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:57.512463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397263 | REC_0002709 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 8 | 86 | female | 2 | 41 | 5.6 | 4 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:57.512697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742776 | REC_0002710 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 8 | 69 | female | 0 | 13 | 4.8 | 2 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.512928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653078 | REC_0002711 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.3 | 84 | female | 3 | 6 | 5.8 | 3 | entrectinib 600 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:57.513162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404502 | REC_0002712 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 22.3 | 67 | female | 0 | 19 | 5.2 | 0 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:57.513400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265675 | REC_0002713 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.5 | 73 | female | 1 | 58 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:35:57.513628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537455 | REC_0002714 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.6 | 77 | female | 2 | 12 | 3.1 | 8 | sotorasib 960 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:57.513861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131964 | REC_0002715 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 14.7 | 50 | male | 0 | 7 | 7.9 | 6 | alectinib 600 mg BID | 16.3 | false | MSS | 2026-03-15T05:35:57.514093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634245 | REC_0002716 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 10.5 | 79 | female | 1 | 22 | 5.2 | 2 | alectinib 600 mg BID | 27.1 | false | MSS | 2026-03-15T05:35:57.514327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856014 | REC_0002717 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.3 | 79 | female | 4 | 13 | 4.5 | 4 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:57.514558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498637 | REC_0002718 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.3 | 72 | female | 1 | 12 | 4.5 | 5 | entrectinib 600 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:57.514842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728259 | REC_0002719 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 12.7 | 64 | female | 1 | 11 | 6.8 | 6 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:57.515082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442931 | REC_0002720 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 4.3 | 63 | female | 0 | 7 | 7.6 | 6 | pembrolizumab 200 mg q3w | 7.6 | false | MSS | 2026-03-15T05:35:57.515317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956509 | REC_0002721 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.4 | 62 | male | 1 | 8 | 5.5 | 2 | alectinib 600 mg BID | 23.8 | false | MSS | 2026-03-15T05:35:57.515551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363315 | REC_0002722 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 6.8 | 64 | male | 0 | 16 | 3 | 1 | entrectinib 600 mg daily | 30.2 | true | MSS | 2026-03-15T05:35:57.515782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965606 | REC_0002723 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 7.8 | 67 | female | 1 | 21 | 6.8 | 6 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.516008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607746 | REC_0002724 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 14.2 | 67 | male | 0 | 20 | 4.9 | 2 | entrectinib 600 mg daily | 30.5 | false | MSI-H | 2026-03-15T05:35:57.516331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750301 | REC_0002725 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 6.1 | 61 | female | 0 | 21 | 6.2 | 6 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.516567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521550 | REC_0002726 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 6.2 | 80 | female | 2 | 23 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:57.516795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387438 | REC_0002727 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 16.2 | 61 | male | 1 | 12 | 5.1 | 7 | alectinib 600 mg BID | 6.7 | false | MSI-H | 2026-03-15T05:35:57.517032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304957 | REC_0002728 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 7.8 | 71 | female | 1 | 19 | 6.9 | 1 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:57.517259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535685 | REC_0002729 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 14.2 | 62 | male | 1 | 28 | 5.9 | 6 | entrectinib 600 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:57.517496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584484 | REC_0002730 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 3.7 | 68 | female | 0 | 23 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:35:57.517727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160402 | REC_0002731 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.9 | 77 | female | 2 | 25 | 5.6 | 6 | entrectinib 600 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:57.518006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512799 | REC_0002732 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.4 | 67 | female | 0 | 10 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.9 | true | MSS | 2026-03-15T05:35:57.518236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780402 | REC_0002733 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.1 | 71 | female | 1 | 20 | 4 | 5 | entrectinib 600 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:57.518466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510628 | REC_0002734 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 9.4 | 81 | female | 2 | 14 | 4 | 1 | osimertinib 80 mg daily | 26.9 | false | MSS | 2026-03-15T05:35:57.518699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519753 | REC_0002735 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.2 | 60 | female | 1 | 16 | 3 | 1 | sotorasib 960 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:57.518956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153809 | REC_0002736 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 7.5 | 70 | male | 3 | 16 | 5.4 | 5 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.519208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941406 | REC_0002737 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 8.8 | 75 | male | 3 | 14 | 6.3 | 2 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:57.519469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356124 | REC_0002738 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18.1 | 62 | male | 0 | 22 | 5.8 | 8 | sotorasib 960 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:57.519727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276352 | REC_0002739 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.7 | 70 | female | 2 | 18 | 7.3 | 2 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:57.519966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487828 | REC_0002740 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.8 | 73 | male | 2 | 19 | 7.3 | 7 | alectinib 600 mg BID | 9.6 | false | MSI-H | 2026-03-15T05:35:57.520285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394020 | REC_0002741 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 9.2 | 72 | female | 2 | 4 | 6.4 | 5 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:35:57.520537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119051 | REC_0002742 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11.7 | 74 | female | 1 | 19 | 4.6 | 5 | alectinib 600 mg BID | 6.4 | false | MSI-H | 2026-03-15T05:35:57.520776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673375 | REC_0002743 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 6.5 | 71 | female | 1 | 12 | 5.4 | 2 | sotorasib 960 mg daily | 27.5 | false | MSS | 2026-03-15T05:35:57.521013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560560 | REC_0002744 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.7 | 50 | female | 0 | 53 | 7.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:57.521364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378447 | REC_0002745 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.4 | 73 | female | 2 | 10 | 6.1 | 1 | entrectinib 600 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:57.521613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438184 | REC_0002746 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 31 | 5.2 | 79 | female | 2 | 16 | 7.6 | 0 | pembrolizumab 200 mg q3w | 45.2 | false | MSS | 2026-03-15T05:35:57.521844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517232 | REC_0002747 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 17.2 | 75 | female | 1 | 25 | 6.3 | 7 | sotorasib 960 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:57.522082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317928 | REC_0002748 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.9 | 70 | female | 1 | 14 | 6.8 | 2 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:57.522315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449562 | REC_0002749 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 12.7 | 65 | female | 1 | 11 | 4.9 | 6 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:57.522553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233334 | REC_0002750 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.5 | 54 | female | 0 | 18 | 4.2 | 7 | osimertinib 80 mg daily | 5.3 | false | MSS | 2026-03-15T05:35:57.522788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166906 | REC_0002751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 14.9 | 78 | female | 1 | 7 | 6 | 2 | entrectinib 600 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.523020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525534 | REC_0002752 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.3 | 48 | female | 0 | 8 | 6.1 | 2 | alectinib 600 mg BID | 21.2 | true | MSS | 2026-03-15T05:35:57.523254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548522 | REC_0002753 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 8.3 | 63 | male | 1 | 2 | 6.3 | 6 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.523484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536489 | REC_0002754 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 13 | 19.1 | 58 | male | 1 | 12 | 5.8 | 5 | pembrolizumab 200 mg q3w | 13.3 | false | MSI-H | 2026-03-15T05:35:57.523719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842085 | REC_0002755 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 8.2 | 50 | male | 0 | 10 | 4.7 | 4 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:35:57.523951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430300 | REC_0002756 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.9 | 76 | female | 1 | 32 | 7.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:57.524228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591608 | REC_0002757 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.4 | 73 | female | 2 | 10 | 4.4 | 6 | sotorasib 960 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:57.524517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198628 | REC_0002758 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.9 | 70 | female | 2 | 10 | 4.5 | 8 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.524754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250372 | REC_0002759 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.9 | 73 | female | 2 | 38 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:35:57.524989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446164 | REC_0002760 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.1 | 68 | female | 1 | 11 | 5 | 4 | alectinib 600 mg BID | 10.4 | true | MSI-H | 2026-03-15T05:35:57.525224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960973 | REC_0002761 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.4 | 65 | female | 1 | 47 | 5.9 | 4 | pembrolizumab 200 mg q3w | 10.9 | true | MSS | 2026-03-15T05:35:57.525456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770309 | REC_0002762 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 22.2 | 76 | female | 1 | 4 | 6.7 | 1 | alectinib 600 mg BID | 19.3 | false | MSS | 2026-03-15T05:35:57.525692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492552 | REC_0002763 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13.7 | 71 | male | 2 | 12 | 4.1 | 5 | sotorasib 960 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:57.525937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938564 | REC_0002764 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.6 | 66 | male | 0 | 5 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:35:57.526170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139712 | REC_0002765 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 3.1 | 51 | female | 0 | 12 | 6.1 | 2 | pembrolizumab 200 mg q3w | 18.9 | false | MSS | 2026-03-15T05:35:57.526401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596087 | REC_0002766 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 29 | 7.7 | 64 | female | 1 | 5 | 5 | 0 | alectinib 600 mg BID | 49.8 | true | MSS | 2026-03-15T05:35:57.526635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149863 | REC_0002767 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.9 | 69 | female | 1 | 18 | 4.2 | 7 | entrectinib 600 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:57.526872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250779 | REC_0002768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 10.7 | 70 | female | 1 | 17 | 4.9 | 6 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:35:57.527104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244836 | REC_0002769 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.5 | 69 | female | 1 | 39 | 7.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.3 | false | MSS | 2026-03-15T05:35:57.527337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849545 | REC_0002770 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.8 | 57 | female | 0 | 42 | 4.9 | 2 | pembrolizumab 200 mg q3w | 7.3 | true | MSS | 2026-03-15T05:35:57.527614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594297 | REC_0002771 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.2 | 67 | female | 1 | 24 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:57.527847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990354 | REC_0002772 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 6.1 | 76 | female | 2 | 19 | 5.5 | 1 | osimertinib 80 mg daily | 24.7 | true | MSS | 2026-03-15T05:35:57.528165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715812 | REC_0002773 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.7 | 72 | female | 1 | 22 | 5.5 | 1 | entrectinib 600 mg daily | 25 | false | MSI-H | 2026-03-15T05:35:57.528412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752446 | REC_0002774 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6 | 73 | male | 1 | 42 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 13 | false | MSS | 2026-03-15T05:35:57.528647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586161 | REC_0002775 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.8 | 56 | male | 0 | 3 | 4.1 | 2 | alectinib 600 mg BID | 10.3 | false | MSI-H | 2026-03-15T05:35:57.528883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577755 | REC_0002776 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 15.1 | 65 | female | 0 | 8 | 5.6 | 2 | sotorasib 960 mg daily | 20.8 | false | MSI-H | 2026-03-15T05:35:57.529121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996991 | REC_0002777 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 14.1 | 80 | female | 1 | 23 | 7 | 5 | osimertinib 80 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:57.529355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811147 | REC_0002778 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11 | 69 | male | 0 | 8 | 5.3 | 2 | entrectinib 600 mg daily | 22.2 | false | MSS | 2026-03-15T05:35:57.529590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414499 | REC_0002779 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.7 | 61 | female | 0 | 63 | 6.3 | 4 | pembrolizumab 200 mg q3w | 7.1 | false | MSS | 2026-03-15T05:35:57.529824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137397 | REC_0002780 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 8.5 | 69 | female | 0 | 19 | 3.5 | 1 | sotorasib 960 mg daily | 26.2 | false | MSS | 2026-03-15T05:35:57.530053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877332 | REC_0002781 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.4 | 68 | male | 0 | 79 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:57.530285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380023 | REC_0002782 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.8 | 60 | male | 1 | 66 | 5.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:57.530512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876362 | REC_0002783 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 18.1 | 54 | male | 0 | 13 | 4.8 | 1 | alectinib 600 mg BID | 11.1 | true | MSI-H | 2026-03-15T05:35:57.530820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787202 | REC_0002784 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10.5 | 63 | female | 0 | 20 | 4.8 | 5 | entrectinib 600 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:57.531059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667986 | REC_0002785 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 8.8 | 55 | female | 1 | 11 | 7.3 | 1 | entrectinib 600 mg daily | 28.7 | false | MSS | 2026-03-15T05:35:57.531294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470118 | REC_0002786 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 16 | 59 | male | 1 | 10 | 6.4 | 6 | alectinib 600 mg BID | 16.8 | false | MSS | 2026-03-15T05:35:57.531528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407448 | REC_0002787 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.9 | 65 | female | 0 | 21 | 5.7 | 1 | entrectinib 600 mg daily | 23.5 | false | MSS | 2026-03-15T05:35:57.531763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660471 | REC_0002788 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8.3 | 75 | female | 1 | 13 | 5.8 | 7 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.531994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253628 | REC_0002789 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12 | 65 | male | 1 | 19 | 5.9 | 4 | alectinib 600 mg BID | 10.9 | true | MSI-H | 2026-03-15T05:35:57.532290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763421 | REC_0002790 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.6 | 65 | male | 0 | 22 | 7.9 | 5 | sotorasib 960 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.532532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750914 | REC_0002791 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.5 | 55 | male | 1 | 17 | 5.5 | 1 | osimertinib 80 mg daily | 18.5 | true | MSS | 2026-03-15T05:35:57.532771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809528 | REC_0002792 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 23.2 | 79 | female | 1 | 14 | 6.8 | 1 | sotorasib 960 mg daily | 30.8 | true | MSS | 2026-03-15T05:35:57.533010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514682 | REC_0002793 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 7.2 | 40 | female | 0 | 15 | 4.6 | 2 | sotorasib 960 mg daily | 18 | false | MSS | 2026-03-15T05:35:57.533244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356008 | REC_0002794 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 9.3 | 58 | male | 0 | 17 | 4.8 | 0 | osimertinib 80 mg daily | 21.1 | false | MSS | 2026-03-15T05:35:57.533474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150174 | REC_0002795 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 20.4 | 66 | female | 0 | 21 | 6.2 | 5 | sotorasib 960 mg daily | 7.9 | false | MSI-H | 2026-03-15T05:35:57.533707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606128 | REC_0002796 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.1 | 70 | female | 2 | 14 | 4.8 | 7 | entrectinib 600 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:57.533987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685970 | REC_0002797 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.4 | 73 | female | 2 | 22 | 5.5 | 5 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:57.534223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842223 | REC_0002798 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.9 | 79 | female | 1 | 6 | 5.7 | 2 | osimertinib 80 mg daily | 27.6 | false | MSS | 2026-03-15T05:35:57.534454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931759 | REC_0002799 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.7 | 70 | male | 1 | 22 | 3.9 | 7 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:57.534690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644599 | REC_0002800 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 12.2 | 53 | female | 0 | 20 | 5.3 | 2 | osimertinib 80 mg daily | 18.9 | true | MSI-H | 2026-03-15T05:35:57.534923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.